GlassScriptPhysician profile
Paul Duncan Boyd
NPI 1699250886
$4,133.34
in general payments reported to CMS, 2019-2025
30 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $911 · 2023: $891 · 2024: $913 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $657.80 | 2021-2025 | |
| Amgen INC. | $462.33 | 2022-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.80 | 2021-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $220.10 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $189.78 | 2021-2025 | Pifeltro |
| Novartis Pharmaceuticals Corporation | $182.56 | 2021-2023 | |
| Boston Scientific Corporation | $173.04 | 2022-2023 | Watchman |
| Viiv Healthcare Company | $172.65 | 2022-2025 | Apretude, Dovato |
| Kowa Pharmaceuticals America, INC. | $171.19 | 2021-2022 | |
| Amarin Pharma, INC. | $163.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $162.43 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $160.24 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $131.14 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $119.63 | 2023-2025 | Voquezna |
| Abbvie INC. | $110.52 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.94 | 2021-2025 | |
| Esperion Therapeutics, INC. | $88.60 | 2021-2025 | Nexletol |
| Seqirus USA INC | $87.71 | 2022-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Idorsia Pharmaceuticals US INC | $84.95 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $79.41 | 2022-2025 | Spravato |
| Astellas Pharma US INC | $78.41 | 2023-2025 | Veozah |
| Sanofi Pasteur INC. | $69.37 | 2023-2024 | |
| Shield Therapeutics INC | $62.52 | 2024 | |
| Janssen Biotech, INC. | $43.68 | 2023 | Symtuza |
| Otsuka America Pharmaceutical, INC. | $42.27 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $21.84 | 2022 | |
| Edwards Lifesciences Corporation | $21.21 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corcept Therapeutics | $20.26 | 2021 | |
| Mylan Specialty L.P. | $17.79 | 2021 | |
| Tolmar, INC. | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.